ClinicalTrials.gg
RecruitingNCT06584552Updated Jun 3, 2025

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

A Phase 2 interventional study of Lactobacillus Paracasei LPB27 and Maltodextrin in Eczema and Allergy, sponsored by The University of New South Wales. Recruiting at 1 site in Australia. Open to participants aged 3 Months to 3 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by The University of New South Wales · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
3 Months to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Eczema with a site in Australia — 4 open to participants now, 9 under way, 3 of them phase 3. Eczema · Australia.

Planned enrollment
35th of 40
100 · median 389
Started
2024
with 2 others
Phase 2
16 of 41
3 open now
Registered
38th of 41
by date

Among the 41 studies in Eczema with a site in Australia, this one is the 35th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 in phase 2, and was the 38th registered.

Eczema

507 studies on the registry are indexed under Eczema; 91 are open to participants now.

Browse Eczema studies →

Open to participants now

4 of the 41 studies in Eczema with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 3 Months to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Eczema with a site in Australia, or all of them as a file.
02

Study summary

The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.

Read the detailed description

Childhood eczema is a common and chronic, relapsing disease of the skin which affects up to 20% of the paediatric population. Eczema has significant impact on the quality of life of those affected. Its main symptoms are dry skin and intense itching.

There is currently no cure for eczema but there are treatments that try to relieve symptoms. These commonly include topical moisturisers and topical corticosteroids.

Although topical corticosteroids are effective in minimising symptoms, there is a prevailing and universal fear of using topical corticosteroids which is one of the main reasons for poor treatment compliance.

There have been emerging interests in prevention and treatment of eczema through modulation of the gut microbiome. The gut microbiome is a key regulator for the immune system and there is evidence that the composition of gut microbiome may reduce allergies by driving maturation of the immune system. It was shown that people with eczema have different bacteria in their gut compared to people without eczema. Therefore, this study's hypothesis is that administration of oral probiotics will benefit young children with eczema by improving their gut microbiome and quality of life.

03

Conditions studied

  • Eczema
  • Allergy

Keywords

  • Immunology
  • Microbiome
  • Paediatrics
04

Who can participate

Ages eligible
3 Months to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 3 months to 3 years old
  • Diagnosis: Eczema (atopic dermatitis) diagnosed clinically by a paediatric dermatologist or immunologist.
  • Severity: Investigator Global Assessment for Atopic Dermatitis (IGA) severity of 1-3 (almost clear, mild, moderate) and a SCORAD score greater than 8.7.
  • Willingness and ability of the subject to comply with the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Patients on systemic and/or biologic agents (participants who start systemic immunosuppression and/or biologic agents mid-way through the study will be considered to have not achieved treatment success and will be withdrawn, regardless of their SCORAD index scores).
  • Mothers who are breastfeeding and on probiotics but not willing to stop probiotics.
  • Child already on probiotics and parents not willing to stop during the entire study period ( of 4 weeks; including formulas that contains probiotics).
  • Eczema complicated by active skin infection e.g. impetigo/cellulitis/ eczema herpeticum (can be considered once active infection resolved).
  • Child currently on oral or IV antibiotics (washout period of 4 weeks allowable once antibiotics completed). Participants who require antibiotics after being enrolled in the study may continue on the study as usual.
  • Immunodeficient disorders.
  • Chronic disorder involving the gastrointestinal tract (e.g., inflammatory bowel disease, short gut syndrome, cystic fibrosis).
  • Known to components contained in study product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Lactobacillus Paracasei LPB27

    Formulation: Lactobacillus paracasei LPB27 (10 billion cfu/ serve) and Maltodextrin (up to 1g). Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.

    Dietary Supplement: Lactobacillus Paracasei LPB27

  • Placebo comparator
    Maltodextrin

    Formulation: Maltodextrin 1g Dosage: 1mg daily for 12 weeks. Delivered orally through through breast milk, formula or solid food.

    Other: Maltodextrin

Interventions

  • Dietary supplementLactobacillus Paracasei LPB27

    Probiotic

  • OtherMaltodextrin

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving treatment success

    Clinically meaningful reduction (\>= 8.7 points) in SCORAD index between baseline and 12 weeks without the use of rescue medication (systemic immunosuppression and/or biologic agents)

    Time frame: Between baseline and 12 weeks

Secondary outcomes

  1. Mean change in SCORAD index

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Scoring Atopic Dermatitis (SCORAD) index

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  2. First use of rescue medication

    Time from baseline to first use of rescue medication, up to 12 weeks

    Time frame: From baseline to time of starting rescue medication (up to 12 weeks)

  3. Mean change in RECAP

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Recap of Atopic Eczema (RECAP) score. The RECAP score ranges from a minimum of 0 to a maximum of 28, with higher scores indicating worse outcomes.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  4. Mean change in IDQOL

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Infant Dermatitis Quality of Life (IDQOL) score. The IDQOL score ranges from a minimum of 0 to a maximum of 30, with higher scores indicating worse outcomes.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  5. Mean change in EASI

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Eczema Area and Severity Index (EASI) score. The EASI score ranges from a minimum of 0 to a maximum of 72, with higher scores indicating worse outcomes.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  6. Mean change in IGA

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Investigator Global Assessment for Atopic Dermatitis (IGA) score. The IGA score ranges from a minimum of 0 to a maximum of 4, with higher scores indicating worse outcomes.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  7. Mean change in POEM

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in Patient-Oriented Eczema Measure (POEM) score. The POEM score ranges from a minimum of 0 to a maximum of 28, with higher scores indicating worse outcomes.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  8. Use of topical corticosteroids

    Mean weight (in grams) of topical corticosteroids used by participants during the 12 weeks of the study.

    Time frame: From baseline to 12 weeks

  9. Mean change in TOPICOP score

    Mean change from baseline to 12 weeks in the Topical Corticosteroid Phobia (TOPICOP) score. The TOPICOP score ranges from a minimum of 0 to a maximum with 100, with higher scores indicating greater levels of phobia.

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  10. Mean change in gut microbiota

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in alpha diversity, beta diversity and short chain fatty avid levels measured from stool samples

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

  11. Mean change in skin microbiota

    Mean change from baseline to 12 weeks (or time of starting rescue medication, whichever occurs earlier) in alpha and beta diversity measured from skin swabs

    Time frame: From baseline to 12 weeks or time of starting rescue medication (whichever occurs earlier)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2026, 16 months after the start.

Of 70 phase 2 interventional studies under Eczema, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 5, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Sep 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06584552
Lead sponsor
The University of New South Wales
Collaborators
Evolution Health Pty Ltd
Responsible party
Keith Chee Y. Ooi (Professor, The University of New South Wales) — Principal investigator
First posted
Sep 5, 2024
Start date
Nov 15, 2024
Primary completion
Mar 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 3, 2025

Study contacts

Keith CY Ooi
Contact
keith.ooi@unsw.edu.au
9382 1752 ext. 02
Jessica Halim
Contact
lacestudy_SCH@unsw.edu.au
9382 1752 ext. 02
Keith CY Ooi
principal investigator · University of New South Wales

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion